

HETEROCYCLES, Vol. 75, No. 6, 2008, pp. 1355 - 1370. © The Japan Institute of Heterocyclic Chemistry
Received, 14th December, 2007, Accepted, 8th February, 2008, Published online, 15th February, 2008. COM-07-11303

SYNTHESIS OF 8-HYDROXYIMIDAZO[1,2-*a*]PYRIDINE-2-CARBOXYLIC ACID AND ITS DERIVATIVES

Uroš Grošelj,¹ Jure Bezenšek,¹ Anton Meden,¹ Jurij Svete,^{1*} Branko Stanovnik,^{1*} Marko Oblak,² Petra Štefanič Anderluh,² and Uroš Urleb²

¹Department of Organic Chemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, Aškerčeva 5, P.O. Box 537, 1000 Ljubljana, Slovenia. E-mail: jurij.svete@fkkt.uni-lj.si, branko.stanovnik@fkkt.uni-lj.si

²Lek Pharmaceuticals d.d., Drug Discovery, Verovškova 57, 1526 Ljubljana, Slovenia

Abstract – Two new imidazo[1,2-*a*]pyridines, 8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxylic acid (**4**) and ethyl 8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxylate (**6**) were prepared *via* cyclization of 2-aminopyridin-3-ol (**1**) with bromopyruvic acid (**2**) and ethyl bromopyruvate (**3**), respectively. 8-Hydroxyimidazo[1,2-*a*]pyridine-2-carboxylic acid (**4**) was successfully coupled with various amino acid derivatives *via* its active ester intermediate into the corresponding amides **22-27**. *O*-protected ethyl 8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxylate **11** was transformed into its hydrazide **13**, acyl azide **14**, and amide **15** derivatives.

INTRODUCTION


Numerous reactions resulting in the formation of the imidazo[1,2-*a*]pyridine ring system have been reported. The majority of imidazo[1,2-*a*]pyridines have been prepared by the reaction of a variety of 2-aminopyridines with α -halocarbonyl compounds, usually a ketone or aldehyde. Other methods include cyclizations of 2-aminopyridines with α -dioxo compounds, including α -oxocarboxylic acids derivatives, 1,5-dipolar cyclization, and a number of other reactions which either appear to lack generality for this ring systems, or in which only poor yields have been obtained.^{1,2,3} Recently, a regioselective synthesis of substituted imidazonaphthyridines, azacarboline and cyclazines⁴ and vinyl substituted imidazo[1,2-*a*]pyridines⁵ have been reported.

Imidazo[1,2-*a*]pyridine system has been extensively investigated mainly because of important biological applications, such as antibacterial,⁶ antifungal,⁷ antiviral,⁸ cardiotoxic,⁹ acetylcholinesterase inhibitors,¹⁰ DNA binding ligands targeting drug-resistant bacteria,¹¹ and phosphodiesterase 5 inhibiting activity.¹²

Mur ligases play an essential role in the intracellular biosynthesis of bacterial peptidoglycan, the main component of the bacterial cell wall.¹³ The critical biological function as well as an active site amenable for small molecule inhibition as revealed by crystallographic structures¹⁴ make Mur ligases an attractive target for the discovery of novel antibacterial agents.^{14,15} In this paper, we report the synthesis of 8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxylic acid derivatives as potential inhibitors of Mur ligases.

RESULTS AND DISCUSSION

The starting compounds 8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxylic acid (**4**) and ethyl 8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxylate (**6**) were prepared in 39% and 38% yield, respectively, by cyclocondensation of 2-aminopyridin-3-ol (**1**) with bromopyruvic acid (**2**) and ethyl bromopyruvate (**3**), respectively.¹¹ The formation of compound **6** proceeds *via* the intermediate **5**, which was isolated when the cyclization of **1** with ethyl bromopyruvate (**3**) was carried out in 1,2-dimethoxyethane at room temperature. Treatment of intermediate **5** in ethanol under microwave irradiation at 120 °C gave cyclocondensation product **6**. Attempted formation of methyl ester of **4**, compound **8**, with excess of diazomethane (**7**) performed in different solvents (ethanol, CH₂Cl₂, Et₂O) failed completely probably due to the zwitterionic nature of compound **4**. The unreacted starting compound **4** was successfully recovered (Scheme 1).



Scheme 1. Synthesis of starting compounds **4** and **6**


Next, synthesis of the corresponding hydrazide from ester **6** was attempted. Reaction of **6** with two equivalents of hydrazine monohydrate in ethanol at room temperature gave hydrazinium salt **9** due to the

acidic nature of hydroxy group in position 8. Reactions of **6** with large excess of hydrazine monohydrate at room temperature gave again hydrazinium salt **9**, whereas the same reaction at elevated temperature led to the inseparable mixture of products. In order to prevent the formation of undesired hydrazinium salt **9** and other similar salts, the 8-hydroxy group was protected. Treatment of **6** with *tert*-butyldimethylsilyl chloride in DMF in the presence of imidazole gave TBDMS-protected compound **10**,¹⁶ while Cs₂CO₃ catalyzed reaction of **6** with benzylbromide in THF furnished benzyl protected compound **11**.¹⁷ Alternatively, cyclization of *O*-benzylated 2-aminopyridin-3-ol **12**, prepared from **1** following the modified literature procedure,¹⁸ with ethyl bromopyruvate (**3**) gave **11** in 27% overall yield. Compound **11** prepared *via* the sequence **1**→**6**→**11** was obtained in 21% overall yield. Reaction of compound **10** with basic hydrazine monohydrate in THF induced the TBDMS deprotection and formation of the undesired hydrazinium salt **9**. On the other hand, treatment of **11** with a large excess of hydrazine monohydrate in refluxing THF yielded the desired hydrazide **13**.¹⁹ Diazotization of hydrazide **13** gave acyl azide **14**.⁴ Finally, preparation of the amide **15** was undertaken. Reactions of **11** in liquid ammonia, CHCl₃/NH₃(g), and ethanol/NH₃(g) failed to give the desired product **15**. Reaction of **11** in the mixture of NH₄OH (25% aq)/THF at room temperature for several days gave **15** in 28% conversion. On the other hand, the same reaction in an autoclave at elevated temperature (90 °C) gave amide **15** in full conversion (Scheme 2).

Hydroxy acid **4** was used as the starting compound in the coupling reactions with amine **16** and amino acid derivatives **17-21** to form the corresponding amidation products. Coupling of acid **4** with 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) as activating agent failed to give the desired amides. On the other hand, activation of **4** with bis(pentafluorophenyl) carbonate (BPC) in the presence of Et₃N followed by the addition of amine **16** or amino acid derivatives **17-21** gave the corresponding amides **22-27**.²⁰ Using the BPC activation for the coupling of **4** with different heteroaromatic amines failed completely. Hydrolysis of esters **23-25** with NaOH in a mixture of MeOH/H₂O proceeded smoothly to the acids **28-30**, respectively (Scheme 3, Table 1).²¹


STRUCTURE DETERMINATION

The structures of compounds **4-6**, **9-11**, **13-15**, **22-27**, and **28-30** were determined by spectroscopic methods (IR, ¹H and ¹³C NMR, NOESY spectroscopy, MS) and by elemental analyses for C, H, and N. Compounds **4-6**, **9**, **14**, **22**, **23**, **27**, **28**, and **30** were not prepared in analytically pure form. Identities of compounds **4**, **6**, **9**, **14**, **22**, **23**, **27**, **28**, and **30** were confirmed by ¹³C NMR and/or EI-HRMS. Compounds **5** and **9** were characterized only by ¹H NMR.

Scheme 2. Transformations of compound **6**

X-Ray structure analysis for compound **15**

Single crystal X-ray diffraction data of compound **15** were collected at room temperature on a Nonius Kappa CCD diffractometer using the Nonius Collect Software.²² DENZO and SCALEPACK²³ were used for indexing and scaling of the data and the structure was solved by means of SIR97.²⁴ Refinement was done using Xtal3.4²⁵ program package. Crystal structure was refined on F values using the full-matrix least-squares procedure.

Scheme 3. Synthesis of coupling products **22-27** and methyl ester hydrolysis products **28-30**Table 1. Selected experimental data for compounds **22-30**

Reaction	R	R ¹	Yield (%)
4→22			
4→23			42
4→24			48
4→25			40
4→26			40
4→27			27
23→28			75
24→29			53
25→30		H	63

The non-hydrogen atoms were refined anisotropically, while the positions of hydrogen atoms were geometrically calculated and their positional and isotropic atomic displacement parameters were not refined. Absorption correction was not necessary. Regina²⁶ weighting scheme was used. ORTEP-III²⁷ drawings of the content of asymmetric units of amide **15** showing the atom-labeling scheme is presented in Figure 1.

Crystallographic data (excluding structure factors) for the structure in this paper has been deposited with the Cambridge Crystallographic Data Centre as supplementary publication numbers CCDC 670122. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK [fax: +44(0)-1223-336033 or e-mail: deposit@ccdc.cam.ac.uk].




Figure 1. The asymmetric unit of compound **15**. Ellipsoids are plotted at 50% probability level. H atoms are drawn as circles of arbitrary radii

EXPERIMENTAL

Melting points were determined on a Kofler micro hot stage. The ¹H NMR spectra were obtained on a Bruker Avance DPX 300 at 300 MHz for ¹H and 75.5 MHz for ¹³C nucleus, using DMSO-d₆ and CDCl₃, with TMS as the internal standard, as solvents (δ in ppm, J in Hz). All NMR experiments were carried out

at 302 K. Optical rotations were measured on a Perkin-Elmer 241MC Polarimeter. Mass spectra were recorded on an AutoSpecQ spectrometer and Q-TOF Premier spectrometer, IR spectra on a Perkin-Elmer Spectrum BX FTIR spectrophotometer (ν in cm^{-1}). Microanalyses were performed on a Perkin-Elmer Series II CHN Analyser 2400. Column chromatography (CC) was performed on silica gel (Fluka, silica gel 60, 0.04–0.06 mm).

8-Hydroxyimidazo[1,2-*a*]pyridine-2-carboxylic acid (4) A suspension of 2-aminopyridin-3-ol (**1**) (2.2 g, 20 mmol) in anhydrous MeOH (50 mL) was treated with bromopyruvic acid (**2**) (3.34 mL, 20 mmol) at rt and the resulting mixture was stirred at rt for 24 h. The resulting precipitate was collected by filtration to give **4**. 39% yield (1.39 g) of a greyish-white solid; mp >350 °C. ^1H NMR (DMSO- d_6) δ : 6.53 (1H, dd, $J = 0.9$; 7.5 Hz, Ar); 6.78 (1H, t, $J = 7.2$ Hz, Ar); 8.05 (1H, dd, $J = 0.9$; 6.9 Hz, Ar); 8.44 (1H, s, Ar); 10.57 (1H, br s, OH). m/z (EI) = 178 (M^+); m/z (HRMS) Found: 178.038000 (M^+); $\text{C}_{10}\text{H}_{10}\text{N}_2\text{O}_3$ requires: $m/z = 178.037842$. *Anal.* Calcd for $\text{C}_8\text{H}_6\text{N}_2\text{O}_3$: C, 53.94; H, 3.39; N, 15.73. Found: C, 52.73; H, 3.78; N, 13.23. ν_{max} (KBr) 3446, 3134, 3038, 2934, 1861, 1790, 1645, 1567, 1418, 1393, 1321, 1296, 1234, 1139, 1106, 1060, 1035, 897, 828, 781, 734, 623, 577, 532 cm^{-1} .

2-(Ethoxycarbonyl)-2,8-dihydroxy-2,3-dihydro-1H-imidazo[1,2-*a*]pyridin-4-ium bromide (5) A suspension of 2-aminopyridin-3-ol (**1**) (0.55 g, 5 mmol) in 1,2-dimethoxyethane (25 mL) was treated with ethyl bromopyruvate (**3**) (0.975 g, 5 mmol) at rt. After stirring at rt for 5–10 min the suspension completely dissolved. The reaction mixture was stirred at rt for 18 h. The resulting precipitate was collected by filtration, suspended in MeCN (15 mL) and stirred at rt for 15 min. The suspension was collected by filtration to give **5**. 34% yield (0.550 g) of a white solid; mp 138–141 °C. ^1H NMR (DMSO- d_6) δ : 1.27 (3H, t, $J = 7.2$ Hz, COOEt); 4.24 (2H, q, $J = 7.2$ Hz, COOEt); 4.68 (1H, d, $J = 14.1$ Hz, 1H of CH_2); 5.08 (1H, d, $J = 14.1$ Hz, 1H of CH_2); 6.96 (1H, dd, $J = 6.3$; 7.8 Hz, Ar); 7.37 (1H, d, $J = 7.5$ Hz, Ar); 7.80 (1H, br s); 7.83 (1H, d, $J = 6.6$ Hz, Ar); 10.45 (1H, br s, OH); 11.50 (1H, br s). *Anal.* Calcd for $\text{C}_{10}\text{H}_{13}\text{BrN}_2\text{O}_4$: C, 39.36; H, 4.29; N, 9.18. Found: C, 39.90; H, 4.53; N, 8.00. ν_{max} (KBr) 3344, 3190, 3011, 2946, 1926, 1869, 1743 (C=O), 1656, 1596, 1560, 1428, 1395, 1296, 1273, 1206, 1138, 1104, 1055, 1016, 921, 808, 785, 735 cm^{-1} .

Ethyl 8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxylate (6)

Procedure A: A suspension of 2-(ethoxycarbonyl)-2,8-dihydroxy-2,3-dihydro-1H-imidazo[1,2-*a*]pyridin-4-ium bromide (**5**) (0.153 g, 0.5 mmol) in EtOH (2 mL) was irradiated in a laboratory microwave oven ($P = 300$ W, $T = 120$ °C, $P = 3$ – 5 bar) for 30 min. Volatile components were evaporated *in vacuo* and the residue was purified by CC (ethyl acetate/ethanol, 10:1). Fractions containing the product were combined and evaporated *in vacuo* to give **6**. 38% yield (0.040 g) of a greyish-white solid.

Procedure B: A suspension of 2-aminopyridin-3-ol (**1**) (5.858 g, 53.2 mmol) in anhydrous THF (120 mL) was treated with ethyl bromopyruvate (**3**) (6.65 mL, 53 mmol) at rt and heated at reflux for 40 h. Volatile components were evaporated *in vacuo*, CH₂Cl₂ (200 mL) was added to the residue and the mixture was washed with saturated aqueous sodium bicarbonate solution (100 mL). Aqueous phase was additionally extracted twice with CH₂Cl₂ (50 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered, and the filtrate was evaporated *in vacuo*. The residue was purified by CC (AcOEt/petroleum ether, 3:2 for elution of nonpolar impurities followed by AcOEt for elution of the product **6**). Fractions containing the product were combined and evaporated *in vacuo* to give **6**. 38% yield (4.200 g) of a greyish-white solid; mp 100-130 °C. ¹H NMR (DMSO-*d*₆) δ: 1.32 (3H, t, *J* = 7.2 Hz, COOEt); 4.32 (2H, q, *J* = 7.2 Hz, COOEt); 6.55 (1H, dd, *J* = 0.9; 7.5 Hz, Ar); 6.80 (1H, deg t, *J* = 6.6; 7.5 Hz, Ar); 8.06 (1H, dd, *J* = 0.9; 6.9 Hz, Ar); 8.52 (1H, s, Ar); 10.59 (1H, br s, OH). ¹³C NMR (DMSO-*d*₆) δ: 15.1, 61.0, 106.4, 115.2, 119.5, 119.7, 135.4, 140.9, 147.7, 163.6. *m/z* (EI) = 206 (M⁺); *m/z* (HRMS) Found: 206.069850 (M⁺); C₁₀H₁₀N₂O₃ requires: *m/z* = 206.069142. *Anal.* Calcd for C₁₀H₁₀N₂O₃: C, 58.25; H, 4.89; N, 13.59. Found: C, 56.21; H, 4.79; N, 12.14. *v*_{max} (KBr) 3144, 3115, 2976, 2928, 2541, 1709 (C=O), 1550, 1489, 1475, 1451, 1401, 1384, 1340, 1298, 1256, 1239, 1177, 1137, 1113, 1094, 1030, 991, 926, 909, 869, 840, 817, 779, 758, 740, 729, 714 cm⁻¹.

Hydrazinium 2-(ethoxycarbonyl)imidazo[1,2-*a*]pyridin-8-olate (**9**)

Procedure A: A solution of ethyl 8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxylate (**6**) (0.103 g, 0.5 mmol) in anhydrous EtOH (2 mL) was treated with hydrazine monohydrate (0.049 mL, 1 mmol) and stirred at rt for 48 h. The resulting white precipitate was collected by filtration and washed with ethanol (2 mL) and Et₂O (5 mL) to give **9**. 67% yield (0.080 g) of a greyish-white solid.

Procedure B: A solution of ethyl 8-(*tert*-butyldimethylsilyloxy)imidazo[1,2-*a*]pyridine-2-carboxylate (**10**) (0.091 g, 0.28 mmol) in anhydrous THF (2 mL) was treated with hydrazine monohydrate (0.016 mL, 0.33 mmol) at rt and heated at reflux for 5 h. The resulting precipitate was collected by filtration and washed with EtOH (2 mL) and Et₂O (5 mL) to give **9**. 43% yield (0.029 g) of a greyish-white solid. Melting point: 157-163 °C. ¹H NMR (DMSO-*d*₆) δ: 1.32 (3H, t, *J* = 7.2 Hz, COOEt); 4.31 (2H, q, *J* = 7.2 Hz, COOEt); 4.51 (5H, br s, NH₂NH₃⁺); 6.47 (1H, dd, *J* = 0.9; 7.5 Hz, Ar); 6.77 (1H, deg t, *J* = 6.9; 7.2 Hz, Ar); 7.98 (1H, dd, *J* = 0.9; 6.6 Hz, Ar); 8.49 (1H, s, Ar). *Anal.* Calcd for C₁₀H₁₄N₄O₃: C, 50.41; H, 5.92; N, 23.52. Found: C, 53.24; H, 5.44; N, 19.03. *v*_{max} (KBr) 3446, 3140, 1721 (C=O), 1552, 1525, 1490, 1399, 1387, 1318, 1305, 1226, 1176, 1130, 1030, 985, 775, 734 cm⁻¹.

Ethyl 8-(*tert*-butyldimethylsilyloxy)imidazo[1,2-*a*]pyridine-2-carboxylate (10**)** A solution of ethyl 8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxylate (**6**) (0.279 g, 1.35 mmol), *tert*-butyldimethylsilyl chloride (0.408 g, 2.71 mmol), and imidazole (0.368 g, 5.40 mmol) in DMF (5 mL) was stirred at rt for

24 h. The reaction mixture was poured into water (200 mL) and extracted with petroleum ether (4x50 mL). The combined organic extracts were dried over anhydrous Na₂SO₄, filtered, and the filtrate was evaporated in *vacuo*. The residue was purified by CC (ethyl acetate/petroleum ether, 1:3). Fractions containing the product were combined and evaporated *in vacuo* to give **10**. 78% yield (0.251 g) of a white solid; mp 85-90 °C. ¹H NMR (CDCl₃) δ: 0.33 (6H, s, 2xMe); 1.05 (9H, s, *t*-Bu); 1.41 (3H, t, *J* = 7.2 Hz, COOEt); 4.41 (2H, q, *J* = 7.2 Hz, COOEt); 6.57 (1H, dd, *J* = 0.9; 7.2 Hz, Ar); 6.70 (1H, deg t, *J* = 6.9; 7.2 Hz, Ar); 7.78 (1H, dd, *J* = 0.9; 6.6 Hz, Ar); 8.13 (1H, s, Ar). ¹³C NMR (CDCl₃) δ: -4.2, 14.4, 18.7, 25.9, 60.9, 111.0, 114.0, 117.8, 119.6, 136.2, 142.6, 146.4, 163.5. *Anal.* Calcd for C₁₆H₂₄N₂O₃Si: C, 59.97; H, 7.55; N, 8.74. Found: C, 59.81; H, 7.70; N, 8.62. *v*_{max} (KBr) 3462, 3144, 3107, 2956, 2855, 1715 (C=O), 1550, 1473, 1383, 1361, 1343, 1309, 1273, 1252, 1217, 1187, 1114, 1100, 1054, 1031, 976, 905, 839, 824, 794, 779, 757, 741, 695 cm⁻¹.

Ethyl 8-(benzyloxy)imidazo[1,2-*a*]pyridine-2-carboxylate (**11**)

Procedure A: A mixture of ethyl 8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxylate (**6**) (0.104 g, 0.5 mmol), Cs₂CO₃ (0.326 g, 1 mmol), and benzyl bromide (118 μl, 1 mmol) in THF (5 mL) was stirred at rt for 24 h. Volatile components were evaporated in *vacuo* and the residue was suspended in CH₂Cl₂ (70 mL) and washed with NaHSO₄ (aq sat) (50 mL) and water (50 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered, and the filtrate was evaporated in *vacuo*. The residue was purified by CC (AcOEt/petroleum ether, 2:1). Fractions containing the product were combined and evaporated *in vacuo* to give **11**. The product **11** was recrystallized from the mixture of AcOEt /*n*-heptane. 55% yield (0.082 g) of a white solid; mp 158-165 °C. ¹H NMR (CDCl₃) δ: 1.42 (3H, t, *J* = 7.2 Hz, COOEt); 4.45 (2H, q, *J* = 7.2 Hz, COOEt); 5.34 (2H, s, CH₂); 6.48 (1H, br d, *J* = 7.2 Hz, Ar); 6.68 (1H, deg t, *J* = 6.9; 7.5 Hz, Ar); 7.31-7.40 (3H, m, 3H of Ph); 7.46-7.50 (2H, m, 2H of Ph); 7.74 (1H, dd, *J* = 0.9; 6.9 Hz, Ar); 8.15 (1H, s, Ar). ¹³C NMR (CDCl₃) δ: 14.4, 61.0, 70.8, 103.6, 113.8, 118.0, 119.0, 127.4, 128.1, 128.6, 135.9, 136.3, 140.2, 148.7, 163.2. *m/z* (EI) = 296 (M⁺); *m/z* (HRMS) Found: 296.116650 (M⁺); C₁₇H₁₆N₂O₃ requires: *m/z* = 296.116093. *Anal.* Calcd for C₁₇H₁₆N₂O₃: C, 68.91; H, 5.44; N, 9.45. Found: C, 68.70; H, 5.33; N, 9.39. *v*_{max} (KBr) 3447, 3147, 3108, 1717 (C=O), 1543, 1481, 1438, 1398, 1383, 1350, 1296, 1264, 1212, 1182, 1130, 1105, 1067, 1021, 978, 791, 762, 748, 736, 701 cm⁻¹.

Procedure B: A solution of 3-(benzyloxy)pyridin-2-amine (**12**) (0.400g, 2.0 mmol) in anhydrous EtOH (10 mL) was treated with ethyl bromopyruvate (**3**) (0.39g, 2.0 mmol) and stirred under reflux for 2h. Volatile components were evaporated in *vacuo*, the oily residue was crystallized by addition of water (20 mL), and collected by filtration to give raw product **11**. The raw product **11** was dissolved in hot EtOH (3 mL) and precipitated by addition of water (20 mL). The resulting precipitate was collected by filtration to give pure **11**. 55% yield (0.326 g) of a white solid.

3-(Benzyloxy)pyridin-2-amine (12)¹⁸ To a suspension of 2-amino-3-hydroxypyridine (2.2 g, 20 mmol) in CH₂Cl₂ were added (*n*-Bu)₄NBr (0.07 g, 0.22 mmol) and aqueous NaOH (10 mL, 40%). After a minute of stirring, the suspension dissolved and benzyl chloride (2.9 g, 21.4 mmol) was added. The reaction mixture was stirred for 16 h at rt. The organic phase was separated and the aqueous phase was diluted with water (10 mL) and extracted with CH₂Cl₂ (3x10 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered, and the filtrate was evaporated in *vacuo* to give crude **12**. Crude **12** was purified by recrystallization from EtOH. 49% yield (1.963 g) of a yellow solid; mp 89-91 °C, lit.¹⁸ mp 97-99 °C. ¹H NMR (CDCl₃) δ: 4.70 (2H, s, NH₂); 5.09 (2H, s, CH₂); 6.6 (1H, dd, *J* = 5.1; 7.8 Hz, Ar); 6.98 (1H, dd, *J* = 1.2; 7.8 Hz, Ar); 7.34-7.46 (5H, m, Ph); 7.70 (1H, dd, *J* = 1.3; 5.1 Hz, Ar).

8-(Benzyloxy)imidazo[1,2-*a*]pyridine-2-carbohydrazide (13) A mixture of ethyl 8-(benzyloxy)imidazo[1,2-*a*]pyridine-2-carboxylate (**11**) (0.297 g, 1.0 mmol), and hydrazine monohydrate (1.5 mL) in THF (7 mL) was refluxed for 5 h. The reaction mixture was cooled to rt, Et₂O (15 mL) was added and the resulting precipitate was collected by filtration and washed with Et₂O (10 mL). The collected raw product was suspended in cooled water (50 mL, 5 °C) stirred for 10 minutes and the suspension was collected by filtration and washed with cooled water (100 mL, 5 °C) to give **13**. 78% yield (0.220 g) of a white solid; mp 185-187 °C. ¹H NMR (DMSO-*d*₆) δ: 4.42 (2H, br s, NH₂); 5.31 (2H, s, CH₂); 6.80-6.88 (2H, m, 2H of Ar); 7.34-7.47 (3H, m, 3H of Ph); 7.50-7.54 (2H, m, 2H of Ph); 8.18 (1H, dd, *J* = 1.2; 6.0 Hz, Ar); 8.34 (1H, s, Ar); 9.49 (1H, br s; NH). ¹³C NMR (DMSO-*d*₆) δ: 70.1, 103.9, 112.9, 115.4, 120.2, 128.2, 128.3, 128.5, 136.2, 138.1, 138.7, 147.6, 161.1. *m/z* (EI) = 282 (M⁺); *m/z* (HRMS) Found: 282.112200 (M⁺); C₁₅H₁₄N₄O₂ requires: *m/z* = 282.111676. *Anal.* Calcd for C₁₅H₁₄N₄O₂: C, 63.82; H, 5.00; N, 19.85. Found: C, 63.67; H, 4.96; N, 19.80. *v*_{max} (KBr) 3416, 3333, 3143, 1646 (C=O), 1576, 1563, 1546, 1480, 1456, 1444, 1400, 1387, 1343, 1310, 1267, 1102, 1068, 997, 974, 941, 913, 865, 767, 760, 731, 696 cm⁻¹.

8-(Benzyloxy)imidazo[1,2-*a*]pyridine-2-carbonyl azide (14) To a suspension of 8-(benzyloxy)imidazo[1,2-*a*]pyridine-2-carbohydrazide (**13**) (0.282 g, 1.0 mmol) in water (10 mL) was added hydrochloric acid (37%, 0.20 mL, ~2 mmol) at rt. The resulting mixture was cooled to 0 °C and aqueous NaNO₂ (0.5 M, 5 mL, 2.5 mmol) was added slowly. The reaction mixture was stirred at 0 °C for 1.5 h. The resulting white precipitate was collected by filtration and washed with water (30 mL). The filtrate was suspended in CH₂Cl₂ (150 mL) and washed with NaHCO₃ (aq sat) (50 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered, and the filtrate was evaporated in *vacuo*. The residue was dissolved in a minimal amount of CH₂Cl₂ and precipitated by addition of *n*-heptane. The resulting precipitate was collected by filtration to give **14**. 51% yield (0.150 g) of a grayish-white solid; mp 125-140 °C (decomposition with extrusion of N₂). ¹H NMR (DMSO-*d*₆) δ: 5.30 (2H, s, CH₂); 6.84-6.96

(2H, m, 2H of Ar); 7.37-7.46 (3H, m, 3H of Ph); 7.50-7.54 (2H, m, 2H of Ph); 8.19 (1H, dd, $J = 0.9$; 6.6 Hz, Ar); 8.67 (1H, s, Ar). ^{13}C NMR (DMSO- d_6) δ : 70.1, 104.4, 114.1, 120.2, 120.3, 128.0, 128.2, 128.5, 135.1, 136.1, 140.0, 147.8, 167.6. m/z (EI) = 293 (M^+); m/z (HRMS) Found: 293.091600 (M^+); $\text{C}_{15}\text{H}_{11}\text{N}_5\text{O}_2$ requires: $m/z = 293.091275$. *Anal.* Calcd for $\text{C}_{15}\text{H}_{11}\text{N}_5\text{O}_2$: C, 61.43; H, 3.78; N, 23.88. Found: C, 61.25; H, 3.81; N, 22.90. ν_{max} (KBr) 3448, 2158 (N_3), 1693 (C=O), 1543, 1478, 1454, 1435, 1383, 1353, 1292, 1263, 1186, 1104, 1064, 1049, 976, 949, 845, 801, 781, 760, 739, 701 cm^{-1} .

8-(Benzyloxy)imidazo[1,2-*a*]pyridine-2-carboxamide (15) A mixture of ethyl 8-(benzyloxy)imidazo[1,2-*a*]pyridine-2-carboxylate (**11**) (0.593 g, 2.0 mmol), NH_4OH (aq, 25%) (15 mL), and THF (10 mL) was heated in an autoclave for 48 h. The reaction mixture was cooled to rt, the excess NH_3 and THF were evaporated on a heating plate, the residue was cooled to rt, and the resulting precipitate was collected by filtration and washed with water (10 mL) to give **15**. 80% yield (0.428 g) of a white solid; mp 230-234 °C. ^1H NMR (DMSO- d_6) δ : 5.30 (2H, s, CH_2); 6.79-6.88 (2H, m, 2H of Ar); 7.30 (1H, br s, 1H of NH_2); 7.34-7.46 (3H, m, 3H of Ph); 7.50-7.54 (2H, m, 2H of Ph); 7.68 (1H, br s, 1H of NH_2); 8.18 (1H, dd, $J = 1.2$; 6.3 Hz, Ar); 8.32 (1H, s, Ar). ^{13}C NMR (DMSO- d_6) δ : 70.1, 103.7, 113.0, 115.8, 120.2, 128.2, 128.4, 128.5, 136.1, 138.5, 139.2, 147.6, 164.2. m/z (EI) = 267 (M^+); m/z (HRMS) Found: 267.101000 (M^+); $\text{C}_{15}\text{H}_{13}\text{N}_3\text{O}_2$ requires: $m/z = 267.100777$. *Anal.* Calcd for $\text{C}_{15}\text{H}_{13}\text{N}_3\text{O}_2$: C, 67.40; H, 4.90; N, 15.72. Found: C, 67.38; H, 4.85; N, 15.58. ν_{max} (KBr) 3468, 3285, 1661, 1583, 1544, 1455, 1400, 1384, 1357, 1316, 1276, 1187, 1101, 974, 918, 784, 746 cm^{-1} .

General Procedure for Amidation of 8-Hydroxyimidazo[1,2-*a*]pyridine-2-carboxylic acid (**4**) with BPC as the Activating Reagent.

Triethylamine (0.280 mL, 2 mmol) was added to a suspension of 8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxylic acid (**4**) (0.356 g, 2 mmol) in anhydrous dimethylformamide (10 mL), and the mixture was stirred at rt for 10 min. Bis(pentafluorophenyl) carbonate (BPC) (0.946 g, 2.4 mmol) was added and the mixture was stirred at rt for 12 h. Then, amine hydrochloride **16-21** (2 mmol) and triethylamine (0.560 mL, 4.0 mmol) was added and the mixture was stirred at rt for 12 h. Reaction mixture was evaporated *in vacuo* (0.1 Torr/ 60 °C) to remove all volatile components and the residue was purified by CC. Compounds **22-26** were prepared in this manner. In the case of compound **27**, the residue was suspended in MeOH (11 mL) and stirred at rt for 12 h. The suspension was collected by filtration, the filtrate suspended in MeOH/ CHCl_3 (MeOH/ $\text{CHCl}_3 = 10 \text{ mL}/5 \text{ mL}$), and stirred at rt for 12 h. The suspension was collected by filtration and washed with Et_2O (15 mL) to give pure **27**.

***N*-Benzyl-8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxamide (22)** Benzylamine hydrochloride (**16**) (0.287 g); CC (first elution of nonpolar impurities with AcOEt/petroleum ether = 5:1, followed by elution

of the product **22** with ethyl acetate); 35% yield (0.188 g) of a white solid; mp 199-202 °C. ¹H NMR (DMSO-*d*₆) δ: 4.48 (2H, d, *J* = 6.3 Hz, CH₂); 6.55 (1H, dd, *J* = 0.9; 7.5 Hz, Ar); 6.76 (1H, dd, *J* = 6.9; 7.4 Hz, Ar); 7.23-7.36 (1H, m, Ar); 8.07 (1H, dd, *J* = 0.9; 6.7 Hz, Ar); 8.33 (1H, s, Ar); 8.68 (1H, t, *J* = 6.3 Hz, CONH); 10.50 (1H, br s, Ar-OH). ¹³C NMR (DMSO-*d*₆) δ: 42.1, 105.1, 113.7, 115.4, 118.7, 126.7, 127.4, 128.2, 138.6, 139.2, 139.8, 146.8, 162.2. *m/z* (EI) = 267 (M⁺); *m/z* (HRMS) Found: 267.101230 (M⁺); C₁₅H₁₃N₃O₂ requires: *m/z* = 267.100777. *Anal.* Calcd for C₁₅H₁₃N₃O₂: C, 67.40; H, 4.90; N, 15.72. Found: C, 67.11; H, 4.76; N, 15.50. *v*_{max} (KBr) 3420, 3026, 2926, 1651 (C=O), 1609, 1575, 1545, 1493, 1447, 1401, 1364, 1346, 1298, 1248, 1232, 1055, 890, 726 cm⁻¹.

(S)-Methyl 2-(8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxamido)-3-(1*H*-indol-3-yl)propanoate (23)

L-Tryptophan methyl ester hydrochloride (**17**) (0.510 g); CC (AcOEt); 42% yield (0.320 g) of a yellowish-white solid; mp 108-115 °C; [α]₅₈₉¹⁸ +183.9 (*c* 0.17, CHCl₃). ¹H NMR (DMSO-*d*₆) δ: 3.34 (2H, CH₂); 3.65 (3H, s, COOMe); 4.84-4.91 (1H, m, CH); 6.55 (1H, dd, *J* = 0.9; 7.5 Hz, Ar); 6.75-6.80 (1H, m, Ar); 6.93-6.98 (1H, m, Ar); 7.03-7.08 (1H, m, Ar); 7.14 (1H, d, *J* = 2.4 Hz, Ar); 7.33 (1H, d, *J* = 7.8 Hz, Ar); 7.50 (1H, d, *J* = 7.8 Hz, Ar); 8.06 (1H, dd, *J* = 0.9; 6.6 Hz, Ar); 8.17 (1H, d, *J* = 8.1 Hz, CONH); 8.34 (1H, s, Ar); 10.53 (1H, br s, Ar-OH); 10.87 (1H, br s, NH). ¹³C NMR (CDCl₃) δ: 27.2, 52.2, 52.7, 107.2, 108.8, 111.5, 114.8, 116.3, 118.0, 118.6, 119.2, 122.0, 122.4, 127.1, 136.3, 137.7, 139.7, 145.6, 162.4, 172.9. *m/z* (EI) = 378 (M⁺); *m/z* (HRMS) Found: 378.133520 (M⁺); C₂₀H₁₈N₄O₄ requires: *m/z* = 378.132805. *Anal.* Calcd for C₂₀H₁₈N₄O₄: C, 63.48; H, 4.79; N, 14.81. Found: C, 60.71; H, 4.80; N, 13.61. *v*_{max} (KBr) 3387, 1739 (C=O), 1648 (C=O), 1572, 1518, 1483, 1457, 1438, 1400, 1356, 1346, 1295, 1215, 1179, 1091, 739 cm⁻¹.

(S)-Methyl 3-hydroxy-2-(8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxamido)propanoate (24)

L-Serine methyl ester hydrochloride (**18**) (0.311 g); CC (AcOEt/MeOH = 20:1); 48% yield (0.272 g) of a pink-orange solid; mp 210-215 °C; [α]₅₈₉¹⁸ +40.7 (*c* 0.16, CHCl₃/MeOH = 5:1). ¹H NMR (DMSO-*d*₆) δ: 3.68 (3H, s, COOMe); 3.75 (1H, br d, *J* = 11.4 Hz, H_α of CH₂); 3.91 (1H, br d, *J* = 10.8 Hz, H_β of CH₂); 4.60-4.65 (1H, m, CH); 5.33 (1H, br s, Ser-OH); 6.58 (1H, d, *J* = 7.5 Hz, Ar); 6.79 (1H, deg t, *J* = 6.9; 7.2 Hz, Ar); 8.08 (1H, d, *J* = 6.6 Hz, Ar); 8.18 (1H, d, *J* = 8.4 Hz, CONH); 8.37 (1H, s, Ar); 10.57 (1H, br s, Ar-OH). ¹³C NMR (DMSO-*d*₆) δ: 52.1, 54.1, 61.5, 105.4, 113.9, 115.7, 118.7, 137.8, 139.3, 146.8, 162.0, 171.0. *m/z* (EI) = 279 (M⁺); *m/z* (HRMS) Found: 279.086250 (M⁺); C₁₂H₁₃N₃O₅ requires: *m/z* = 279.085521. *Anal.* Calcd for C₁₂H₁₃N₃O₅: C, 51.61; H, 4.69; N, 15.05. Found: C, 51.34; H, 4.80; N, 14.82. *v*_{max} (KBr) 3346, 3159, 3128, 3089, 1744 (C=O), 1645 (C=O), 1576, 1557, 1535, 1491, 1464, 1438, 1403, 1330, 1301, 1248, 1233, 1213, 1184, 1154, 1097, 1051, 1042, 1002, 732 cm⁻¹.

Methyl 2-(8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxamido)acetate (25) Glycine methyl ester hydrochloride (**19**) (0.251 g); CC (AcOEt); 40% yield (0.200 g) of a white solid; mp 175-178 °C. ¹H NMR (DMSO-*d*₆) δ: 3.66 (3H, s, COOMe); 4.06 (2H, d, *J* = 6.3 Hz, CH₂); 6.57 (1H, dd, *J* = 0.9; 7.5 Hz, Ar); 6.77 (1H, deg t, *J* = 6.6; 7.5 Hz, Ar); 8.07 (1H, dd, *J* = 0.9; 6.6 Hz, Ar); 8.34 (1H, s, Ar); 8.54 (1H, br t, *J* = 6.0 Hz, CONH); 10.55 (1H, br s, Ar-OH). ¹³C NMR (DMSO-*d*₆) δ: 40.6, 51.7, 105.2, 113.7, 115.5, 118.8, 138.1, 139.3, 146.8, 162.6, 170.4. *m/z* (EI) = 249 (M⁺); *m/z* (HRMS) Found: 249.075660 (M⁺); C₁₁H₁₁N₃O₄ requires: *m/z* = 249.074956. *Anal.* Calcd for C₁₁H₁₁N₃O₄: C, 53.01; H, 4.45; N, 16.86. Found: C, 52.81; H, 4.57; N, 16.65. *v*_{max} (KBr) 3379, 3132, 1725 (C=O), 1650 (C=O), 1581, 1556, 1527, 1493, 1465, 1434, 1422, 1405, 1344, 1295, 1267, 1249, 1238, 1181, 1091, 1051, 1030, 1000, 954, 893, 852, 772, 735 cm⁻¹.

***N*-(Cyanomethyl)-8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxamide (26)** Aminoacetonitrile hydrochloride (**20**) (0.185 g); CC (AcOEt); 40% yield (0.176 g) of a greyish-white solid; mp 250-255 °C. ¹H NMR (DMSO-*d*₆) δ: 4.27 (2H, d, *J* = 6.0 Hz, CH₂); 6.58 (1H, d, *J* = 7.5 Hz, Ar); 6.79 (1H, deg t, *J* = 6.9; 7.2 Hz, Ar); 8.08 (1H, d, *J* = 6.6 Hz, Ar); 8.41 (1H, s, Ar); 8.98 (1H, br deg t, *J* = 5.4; 5.7 Hz, CONH); 10.60 (1H, br s, Ar-OH). *m/z* (EI) = 216 (M⁺); *m/z* (HRMS) Found: 216.065320 (M⁺); C₁₀H₈N₄O₂ requires: *m/z* = 216.064726. *Anal.* Calcd for C₁₀H₈N₄O₂: C, 55.55; H, 3.73; N, 25.91. Found: C, 55.49; H, 3.75; N, 25.61. *v*_{max} (KBr) 3377, 3161, 3121, 1677 (C=O), 1578, 1560, 1517, 1485, 1400, 1387, 1378, 1301, 1280, 1236, 1213, 956, 773, 735 cm⁻¹.

***N*-(2-Amino-2-oxoethyl)-8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxamide (27)** Glycinamide hydrochloride (**21**) (0.221 g); 27% yield (0.130 g) of a grey solid; mp 230-235 °C. ¹H NMR (DMSO-*d*₆) δ: 3.90 (2H, d, *J* = 5.4 Hz, CH₂); 6.56 (1H, dd, *J* = 0.9; 7.5 Hz, Ar); 6.77 (1H, deg t, *J* = 6.9; 7.2 Hz, Ar); 7.12 (1H, br s, 1H of CONH₂); 7.45 (1H, br s, 1H of CONH₂); 8.07 (1H, dd, *J* = 0.9; 6.6 Hz, Ar); 8.17 (1H, br t, *J* = 5.4 Hz, CONH); 8.33 (1H, s, Ar); 10.57 (1H, br s, Ar-OH). ¹H NMR (DMSO-*d*₆ + D₂O) δ: 3.93 (2H, s, CH₂); 6.62 (1H, d, *J* = 7.5 Hz, Ar); 6.82 (1H, deg t, *J* = 6.9; 7.2 Hz, Ar); 8.10 (1H, d, *J* = 6.6 Hz, Ar); 8.36 (1H, s, Ar). *m/z* (EI) = 234 (M⁺); *m/z* (HRMS) Found: 234.075860 (M⁺); C₁₀H₁₀N₄O₃ requires: *m/z* = 234.075290. *Anal.* Calcd for C₁₀H₁₀N₄O₃: C, 51.28; H, 4.30; N, 23.92. Found: C, 49.36; H, 4.46; N, 24.19. *v*_{max} (KBr) 3373, 3191, 1670 (C=O), 1649 (C=O), 1640, 1577, 1556, 1523, 1487, 1455, 1429, 1404, 1297, 1267, 1247, 1094, 773, 737 cm⁻¹.

General Procedure for the Methyl Ester Hydrolysis of Compounds 23-25.

NaOH (1 M in H₂O, 1.5 mL) was added to a suspension of compound **23-25** (0.65 mmol) in MeOH (3 mL) and the resulting solution was stirred at rt for 24 h. The reaction mixture was cooled to -5 °C followed by addition of HCl (1 M in H₂O, 1.5 mL) and H₂O (2 mL, 4 °C). The reaction mixture was

stirred at -5 °C for 1 h. The resulting precipitate was collected by filtration and washed with H₂O (5 mL, 4 °C). Compounds **28-30** were prepared in this manner.

(S)-2-(8-Hydroxyimidazo[1,2-*a*]pyridine-2-carboxamido)-3-(1*H*-indol-3-yl)propanoic acid (28)

Prepared from compound **23** (0.246 g); 75% yield (0.178 g) of a white solid; mp 178-185 °C; $[\alpha]_{589}^{21} +20.2$ (*c* 0.25, DMSO). ¹H NMR (DMSO-*d*₆) δ: 3.31-3.34 (2H, m, CH₂); 4.78-4.85 (1H, m, CH); 6.59 (1H, d, *J* = 6.9 Hz, Ar); 6.80 (1H, t, *J* = 6.9; 7.2 Hz, Ar); 6.91-6.96 (1H, m, Ar); 7.02-7.07 (1H, m, Ar); 7.12 (1H, d, *J* = 2.4 Hz, Ar); 7.32 (1H, d, *J* = 7.8 Hz, Ar); 7.53 (1H, d, *J* = 8.1 Hz, Ar); 8.07-8.10 (2H, m, CONH, 1H of Ar); 8.37 (1H, s, Ar); 10.61 (1H, br s, Ar-OH); 10.86 (1H, br s, NH); 12.97 (1H, br s, COOH). ¹³C NMR (DMSO-*d*₆) δ: 27.3, 52.5, 106.1, 109.4, 111.4, 114.2, 115.7, 118.3, 118.5, 118.8, 121.0, 123.7, 127.4, 136.1, 137.3, 138.9, 146.5, 161.5, 173.2. *m/z* (EI) = 364 (M⁺); *m/z* (HRMS) Found: 364.118000 (M⁺); C₁₉H₁₆N₄O₄ requires: *m/z* = 364.117155. *Anal.* Calcd for C₁₉H₁₆N₄O₄: C, 62.63; H, 4.43; N, 15.38. Found: C, 59.19; H, 4.60; N, 14.40. *v*_{max} (KBr) 3406, 3125, 1653, 1577, 1520, 1488, 1458, 1400, 1340, 1300, 1230, 1094, 734 cm⁻¹.

(S)-3-Hydroxy-2-(8-hydroxyimidazo[1,2-*a*]pyridine-2-carboxamido)propanoic acid (29)

Prepared from compound **24** (0.182 g); 53% yield (0.092 g) of a brownish-white solid; mp 255-258 °C; $[\alpha]_{589}^{21} +37.8$ (*c* 0.16, DMSO). ¹H NMR (DMSO-*d*₆) δ: 3.75 (1H, dd, *J* = 3.4; 10.9 Hz, H_α of CH₂); 3.91 (1H, dd, *J* = 3.8; 10.9 Hz, H_β of CH₂); 4.50-4.55 (1H, m, CH); 5.27 (1H, br s, OH); 6.56-6.59 (1H, m, Ar); 6.79 (1H, deg t, *J* = 6.8; 7.5 Hz, Ar); 8.06-8.12 (2H, m, CONH, 1H of Ar); 8.37 (1H, s, Ar); 10.62 (1H, br s, Ar-OH); 12.71 (1H, br s, COOH). ¹³C NMR (DMSO-*d*₆) δ: 54.1, 61.6, 105.5, 113.9, 115.6, 118.8, 138.0, 139.3, 146.7, 161.9, 172.0. *m/z* (EI) = 266 (MH⁺); *m/z* (HRMS) Found: 266.0772 (MH⁺); C₁₁H₁₂N₃O₅ requires: *m/z* = 266.0777. *Anal.* Calcd for C₁₁H₁₁N₃O₅: C, 49.81; H, 4.18; N, 15.84. Found: C, 49.75; H, 4.39; N, 15.55. *v*_{max} (KBr) 3437, 3312, 3118, 2452, 1630, 1578, 1508, 1463, 1430, 1338, 1293, 1247, 1231, 1112, 1056, 1041, 953, 788, 739 cm⁻¹.

2-(8-Hydroxyimidazo[1,2-*a*]pyridine-2-carboxamido)acetic acid (30)

Prepared from compound **25** (0.162 g); 63% yield (0.097 g) of a brownish-white solid; mp 293-300 °C. ¹H NMR (DMSO-*d*₆) δ: 3.98 (2H, d, *J* = 5.7 Hz, CH₂); 6.56 (1H, dd, *J* = 0.9; 7.5 Hz, Ar); 6.77 (1H, deg t, *J* = 6.6; 7.5 Hz, Ar); 8.07 (1H, dd, *J* = 0.9; 6.6 Hz, Ar); 8.34 (1H, s, Ar); 8.35 (1H, br t, *J* = 6.0 Hz, CONH); 10.55 (1H, br s, Ar-OH); 12.62 (1H, br s, COOH). ¹³C NMR (DMSO-*d*₆) δ: 40.7, 105.3, 113.8, 115.5, 118.8, 138.2, 139.3, 146.8, 162.5, 171.3. *m/z* (EI) = 236 (MH⁺); *m/z* (HRMS) Found: 236.0660 (MH⁺); C₁₀H₉N₃O₄ requires: *m/z* = 236.0671. *Anal.* Calcd for C₁₀H₉N₃O₄: C, 51.07; H, 3.86; N, 17.87. Found: C, 49.40; H, 4.45; N, 17.15. *v*_{max} (KBr) 3481, 3316, 3118, 2451, 1633, 1578, 1508, 1451, 1423, 1338, 1306, 1286, 1237, 1094, 946, 838, 789, 739 cm⁻¹.

ACKNOWLEDGEMENTS

This work was supported by the funds from Lek Pharmaceuticals d.d., the European Union FP6 Integrated Project EUR-INTAFAR (Project n° LSHM-CT-2004-512138) under the thematic priority Life Sciences, Genomics and Biotechnology for Health.

The financial support from the Ministry of Higher Education, Science and Technology, Slovenia through grants P0-0502-0103, P1-0179, and J1-6689-0103-04 is gratefully acknowledged.

Crystallographic data were collected on the Kappa CCD Nonius diffractometer in the Laboratory of Inorganic Chemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, Slovenia. We acknowledge with thanks the financial contribution of the Ministry of Science and Technology, Republic of Slovenia through grant Packet X-2000 and PS-511-102, which thus made the purchase of the apparatus possible.

REFERENCES

1. J. A. Montgomery and J. A. Secrist III, *Other Imidazoles with Fused Six-membered Rings* in: *Comprehensive Heterocyclic Chemistry I*, ed. by A. R. Katritzky and C. W. Rees, **Vol. 5**, Part 4A, K. T. Potts, Vol. Ed., Pergamon Press 1984, pp. 607-668.
2. A. S. Howard, *Bicyclic 5-6 Systems with One Ring Junction Nitrogen Atom: One Extra Heteroatom 1:0* in: *Comprehensive Heterocyclic Chemistry II*, ed. by A. R. Katritzky, C. W. Rees, and E. F. V. Scriven, **Vol. 8**, G. Jones, Vol. Ed., Elsevier Science Publishing Company 1996, pp. 249-286.
3. G. Hajos and Z. Riedl, *Product class 5: Azaindolizines with Two Nitrogen Atoms in the Five-Membered Ring* in: *Houben-Weyl Methods of Molecular Transformations Science of Synthesis; Heteroarenes and Related Ring Systems*, Georg Thieme Verlag, Stuttgart 2002, **Vol. 12**, pp. 613-678.
4. J. M. Chezal, E. Moreau, O. Chavignon, V. Gaumet, J. Metin, Y. Blache, A. Diez, X. Fradera, J. Luque, and J. C. Teulade, *Tetrahedron*, 2002, **58**, 295.
5. O. Chavignon, J. C. Teulade, M. Madesclaire, A. Gueiffier, Y. Blache, H. Viols, J. P. Chapat, and G. Dauphin, *J. Heterocycl. Chem.*, 1992, **29**, 691.
6. G. Grassy, J.-C. Teulade, J.-P. Chapat, M. Simeon de Buochberg, and M. Attisso, *Eur. J. Med. Chem.*, 1982, **17**, 109.
7. Y. Rival, A. Taudou, and R. Ecalle, *Farmaco*, 1993, **48**, 857.
8. A. Elhakmaoui, A. Gueiffier, J.-C. Milhavet, Y. Blache, J.-P. Chapat, O. Chavignon, J.-C. Teulade, R. Snoeck, G. Andrei, and E. De Clercq, *Bioorg. Med. Chem. Lett.*, 1994, **16**, 1937.
9. M. Yamanaka, S. Suda, Y. Kabasawa, T. Kawamura, T. Ogawa, K. Sawada, and H. Ohhara, *Chem. Pharm. Bull.*, 1992, **40**, 1486.
10. R. J. Sundberg, D. Dalvie, J. Cordero, and H. A. Musallam, *Chem. Res. Toxicol.*, 1993, **6**, 506.

11. J. A. Kaizerman, M. I. Gross, Y. Ge, S. White, W. Hu, J.-X. Duan, E. E. Baird, K. W. Johnson, R. D. Tanaka, H. E. Moser, and R. W. Burli, *J. Med. Chem.*, 2003, **46**, 3914.
12. G. Xia, J. Li, A. Peng, S. Lai, S. Zhang, J. Shen, Z. Liu, X. Chen, and R. Ji, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 2790.
13. A. El Zoeiby, F. Sanschagrin, and R. C. Levesque, *Mol. Microbiol.*, 2003, **47**, 1.
14. M. Kotnik, J. Humljan, C. Contreras-Martel, M. Oblak, K. Kristan, M. Herve, D. Blanot, U. Urleb, S. Gobec, A. Dessen, and T. Solmajer, *J. Mol. Biol.*, 2007, **370**, 107.
15. M. Kotnik, P. Štefanič Anderluh, and A. Prezelj, *Curr. Pharm. Des.*, 2007, **13**, 2283.
16. R. C. Ronald, J. M. Lansinger, T. S. Lillie, and C. J. Wheeler, *J. Org. Chem.*, 1982, **47**, 2541.
17. M. C. Venuti, B. E. Loe, G. H. Jones, and J. M. Young, *J. Med. Chem.*, 1988, **31**, 2132.
18. J. A. Bristol, I. Gross, and R. G. Lovey, *Synthesis*, 1981, **12**, 971.
19. G. Turan-Zitouni, Y. Blache, and K. Güven, *Boll. Chim. Farmac.*, 2001, **140**, 397.
20. Č. Malavašič, B. Brulc, P. Čebašek, G. Dahmann, N. Heine, D. Bevk, U. Grošelj, A. Meden, B. Stanovnik, and J. Svete, *J. Comb. Chem.*, 2006, **9**, 219.
21. R. C. Ronald, J. M. Lansinger, T. S. Lillie, and C. J. Wheeler, *J. Org. Chem.*, 1962, **27**, 4236.
22. Collect Software. Nonius, BV, Delft, The Netherlands, 1998.
23. Z. Otwinowski and W. Minor, *Methods Enzymol.*, 1997, **276**, 307.
24. A. Altomare, M. C. Burla, M. Camalli, G. L. Casciarano, C. Giacovazzo, A. Guagliardi, A. G. G. Moliterni, G. Polidori, and R. Spagna, *J. Appl. Cryst.*, 1999, **32**, 115.
25. S. R. Hall, G. S. D. King, and J. M. Stewart, *The Xtal3.4 User's Manual*; University of Western Australia: Lamb, Perth, 1995.
26. H. Wang and B. E. Robertson, *Structure and Statistics in Crystallography*, ed. by A. J. C. Wilson, Adenine Press: New York, 1985.
27. M. N. Burnett and C. K. Johnson, In *ORTEP-III: Oak Ridge Thermal Ellipsoid Plot Program for Crystal Structure Illustrations*, Oak Ridge National Laboratory Report ORNL-6895, 1996.